The endothelin system is one of the most potent regulators of vascular tone in the human body. Endothelin-1 (ET-1) acts through two receptor subtypes — EDNRA (type A) and EDNRB (type B) — to orchestrate vasoconstriction, vascular smooth muscle proliferation, and arterial wall remodeling. EDNRA is the dominant receptor in vascular smooth muscle and mediates the sustained vasoconstrictive response that maintains cerebrovascular tone¹¹ mediates the sustained vasoconstrictive response that maintains cerebrovascular tone
EDNRA activates Gq-protein signaling, driving IP3-mediated calcium release and PKC activation in smooth muscle cells, producing contraction that can last minutes to hours. rs6841581 sits approximately 900 bp upstream of the EDNRA coding sequence in a region that controls how much receptor protein the cell produces — and one allele makes substantially less of it.

The Mechanism

rs6841581 is a regulatory variant, not a protein-coding change. It lies in the promoter or 5' regulatory region of EDNRA on chromosome 4q31.22 and alters the binding affinity of nuclear transcription factors. Low et al. (2012, Hum Mol Genet) demonstrated that the two alleles of rs6841581 have measurably different affinities for a nuclear protein, and that the susceptible allele drives significantly lower transcriptional activity in luciferase reporter assays²² Low et al. (2012, Hum Mol Genet) demonstrated that the two alleles of rs6841581 have measurably different affinities for a nuclear protein, and that the susceptible allele drives significantly lower transcriptional activity in luciferase reporter assays
Low SK et al. "Genome-wide association study for intracranial aneurysm in the Japanese population identifies three candidate susceptible loci and a functional genetic variant at EDNRA." Human Molecular Genetics, 2012. The result is that carriers of the A allele produce less EDNRA protein per cell.

With fewer functional EDNRA receptors on vascular smooth muscle, the vasoconstrictive response to endothelin-1 is blunted. In cerebral arteries, this impairs the normal maintenance of wall tension and hemodynamic resistance. A heterozygous EDNRA deletion rat model confirmed that reduced EDNRA function is sufficient to trigger intracranial aneurysm formation when combined with hypertensive stress³³ A heterozygous EDNRA deletion rat model confirmed that reduced EDNRA function is sufficient to trigger intracranial aneurysm formation when combined with hypertensive stress
Lampmann et al. 2022 (Brain Sci); EDNRA mutant rats showed more extensive aneurysm formation than wild-type controls under equivalent hypertensive conditions. This animal model provides direct causal evidence that the GWAS signal at rs6841581 reflects true EDNRA dysfunction rather than an indirect association.

The Evidence

The original discovery GWAS by Yasuno et al. (2011, PNAS), combining Japanese discovery cohorts with European replication, linked rs6841581 to intracranial aneurysm risk across 5,891 cases and 14,181 controls⁴⁴ The original discovery GWAS by Yasuno et al. (2011, PNAS), combining Japanese discovery cohorts with European replication, linked rs6841581 to intracranial aneurysm risk across 5,891 cases and 14,181 controls
Yasuno K et al. "Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk." Proc Natl Acad Sci USA, 2011. The association reached genome-wide significance (OR 1.22, P = 2.2 × 10⁻⁸) and held in both East Asian and European populations, making it one of the first trans-ethnic GWAS findings in cerebrovascular genetics.

A meta-analysis of more than 116,000 individuals across 61 studies confirmed rs6841581 as among the most robust genetic risk factors for sporadic intracranial aneurysm (OR 1.22, 95% CI 1.14–1.31)⁵⁵ A meta-analysis of more than 116,000 individuals across 61 studies confirmed rs6841581 as among the most robust genetic risk factors for sporadic intracranial aneurysm (OR 1.22, 95% CI 1.14–1.31)
Alg VS et al. Neurology, 2013. The consistency of effect across diverse populations and study designs places this association in the strong evidence tier for genetic risk research.

An updated East Asian meta-analysis encompassing 20,609 individuals across 6 populations (Hong et al. 2019, World Neurosurg) refined the estimate to OR 1.244 (95% CI 1.174–1.318, P = 1.36 × 10⁻¹³)⁶⁶ An updated East Asian meta-analysis encompassing 20,609 individuals across 6 populations (Hong et al. 2019, World Neurosurg) refined the estimate to OR 1.244 (95% CI 1.174–1.318, P = 1.36 × 10⁻¹³)
Hong EP et al. "Association of Endothelin Receptor Type A with Intracranial Aneurysm in 20,609 East Asians.". The A allele frequency is nearly twice as high in East Asian populations (~28%) compared to Europeans (~14%), meaning the absolute genetic attributable risk is greater in East Asian individuals.

Genome-wide pairwise interaction analyses in a Korean cohort identified 11 SNPs showing genome-wide significant interactions with rs6841581, including variants in RYK (a Wnt co-receptor implicated in vascular development) and TNIK (a MAP3K involved in cytoskeletal regulation)⁷⁷ Genome-wide pairwise interaction analyses in a Korean cohort identified 11 SNPs showing genome-wide significant interactions with rs6841581, including variants in RYK (a Wnt co-receptor implicated in vascular development) and TNIK (a MAP3K involved in cytoskeletal regulation)
Hong EP et al. J Korean Neurosurg Soc, 2023. This interaction architecture suggests that rs6841581's effect on IA risk is amplified by co-occurring variants in vascular developmental pathways.

Practical Actions

Carriers of one or two A alleles at rs6841581 face an incrementally elevated lifetime risk of intracranial aneurysm (unruptured or ruptured as subarachnoid hemorrhage). The per-allele OR of ~1.22–1.24 is modest in absolute terms — population prevalence of unruptured intracranial aneurysms is roughly 2–5% — but the risk is amplifiable by modifiable factors including uncontrolled hypertension and smoking, both of which are potent independent risk factors for aneurysm formation and rupture.

Blood pressure management is the most evidence-supported modifiable lever. The EDNRA pathway mediates ET-1-driven vasoconstriction; reduced EDNRA signaling already impairs vascular wall tension maintenance, and superimposed hypertension exacerbates the hemodynamic stress that triggers aneurysm development. Smoking independently upregulates ET-1 production and promotes vascular inflammation, creating a compounding pro-aneurysm environment for A allele carriers.

MRI angiography (MRA) without contrast can detect unruptured intracranial aneurysms ≥3 mm with high sensitivity and involves no radiation. For A allele carriers with additional risk factors (family history of IA or subarachnoid hemorrhage, hypertension, or smoking history), discussing screening MRA with a neurologist or vascular neurosurgeon is a proportionate response to the genetic finding.

Interactions

rs5335, a 3'UTR variant in the same EDNRA gene, also alters EDNRA expression and is associated with blood pressure variation. Carrying risk alleles at both rs6841581 and rs5335 would be expected to compound the EDNRA downregulation phenotype. The two variants are located at opposite ends of the EDNRA gene (rs6841581 upstream regulatory vs. rs5335 3'UTR) and likely act through independent regulatory mechanisms.

rs6842241, a nearby intergenic variant in the same GWAS locus (Low et al. 2012, OR 1.25), may tag the same functional haplotype as rs6841581 or represent a second independent signal at the EDNRA locus. Both are captured when sequencing this chromosomal region.

rs767603 (LOC105378189) is another intracranial aneurysm susceptibility locus in the heart_inflammation category — the two variants act through independent mechanisms (EDNRA downregulation vs. putative non-coding RNA regulation of vascular wall integrity genes). Both A allele carriers at rs6841581 and T allele carriers at rs767603 benefit from the same blood pressure and smoking avoidance actions.

Alpha-1 antitrypsin (AAT), encoded by SERPINA1, is the body's most abundant serine protease inhibitor and serves as the primary natural inhibitor of Proteinase 3 (PR3)¹¹ primary natural inhibitor of Proteinase 3 (PR3)
PR3 is a neutrophil-derived serine protease that is the main antigenic target of PR3-ANCA antibodies in granulomatosis with polyangiitis (GPA). When AAT function is compromised, unbound PR3 accumulates on neutrophil surfaces and in the circulation, driving autoantibody formation and vascular inflammation. The rs7151526 variant lies approximately 6.7 kilobases downstream of the SERPINA1 coding sequence, in a non-coding regulatory region near the gene's 3' flank. Though not itself a coding change, it has been identified as a risk factor for ANCA-associated vasculitis (AAV)²² ANCA-associated vasculitis (AAV)
AAV encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA — a group of rare but serious autoimmune conditions affecting small blood vessels, with the A allele significantly overrepresented among GPA patients.

The Mechanism

SERPINA1 encodes AAT, whose primary job is to neutralize PR3 released by activated neutrophils during inflammatory episodes. When PR3 is left uninhibited — whether due to reduced AAT levels or impaired AAT function — it can trigger an autoimmune cascade: unbound PR3 on neutrophil surfaces becomes an exposed antigen, stimulating production of anti-PR3 ANCA antibodies. These antibodies then activate more neutrophils in a self-amplifying loop, causing necrotizing inflammation of small vessels — the hallmark of AAV.

The rs7151526 variant is located in a non-coding region (primarily affecting lncRNA transcripts) with "MODIFIER" impact by VEP annotation. Its exact molecular mechanism of action is not fully characterized; however, regulatory variants in the 3' flanking region of genes can affect mRNA stability, expression level, or splicing of nearby transcripts. Research shows that even in patients with normal AAT protein concentrations, AAT functional activity is dramatically lower in Wegener's granulomatosis³³ normal AAT protein concentrations, AAT functional activity is dramatically lower in Wegener's granulomatosis
Mota et al. found TIC and specific AAT activity significantly decreased despite equivalent protein levels (p=0.001), suggesting that subtle changes in AAT expression or function — potentially mediated by non-coding regulatory variants like rs7151526 — can tip the protease-antiprotease balance toward disease.

The Evidence

A meta-analysis of 18 eligible studies⁴⁴ meta-analysis of 18 eligible studies
Banerjee et al., International Journal of Rheumatic Diseases, 2022 confirmed rs7151526-A as a significant predisposing allele for GPA (Meta-OR = 2.70, 95% CI 1.51–4.85, p = 0.0008). This finding was consistent across studies and confirms that carrying the A allele approximately doubles to triples the odds of developing GPA compared to CC homozygotes.

The clinical stakes are considerable. A 2024 prospective cohort study of 115 Brazilian AAV patients⁵⁵ 2024 prospective cohort study of 115 Brazilian AAV patients
Giardini et al., Clinics (São Paulo), 2024 — predominantly GPA (65.2%) — found SERPINA1 polymorphisms to be "the most significant factor linked to mortality" in multivariate analysis (HR = 6.2, 95% CI 1.4–27.1, p = 0.015). Carriers of rs7151526 had a mean survival of 57.4 years, compared to 68.0 years in non-carriers — a reduction of more than a decade. A French retrospective cohort of 142 AAV patients⁶⁶ French retrospective cohort of 142 AAV patients
Deshayes et al., Journal of Rheumatology, 2019 found that patients with deficient AAT alleles had significantly higher rates of intraalveolar hemorrhage (p < 0.01), a severe and potentially fatal pulmonary complication.

Population frequencies confirm this is a predominantly European variant: the A allele occurs at ~4.8% in Europeans, versus ~0.1% in East Asians and ~0.9% in Africans. The overall global minor allele frequency is approximately 3.4% (gnomAD v4). Given the additive genetic architecture and the rarity of AAV itself (~3 per 100,000 per year), the absolute risk increase is modest, but the prognostic impact once disease develops appears substantial.

Practical Actions

Carrying the A allele does not mean you will develop AAV — the condition remains rare even in genetically predisposed individuals, and environmental triggers (infections, silica exposure, drugs) are required. However, awareness of this genetic signal supports a lower threshold for clinical evaluation when relevant symptoms appear. ANCA-associated vasculitis characteristically presents with upper respiratory tract symptoms⁷⁷ upper respiratory tract symptoms
ENT symptoms including chronic sinusitis, nosebleeds, saddle-nose deformity in GPA; subglottic stenosis, lower respiratory disease (cough, hemoptysis), kidney involvement (hematuria, proteinuria, rising creatinine), and systemic features (fatigue, weight loss, fever). Prompt ANCA testing and rheumatology referral at symptom onset significantly improves outcomes.

For those who carry this variant, early disease recognition is the most actionable step. ANCA-associated vasculitis treated in early disease stages — before irreversible organ damage — has substantially better outcomes than disease diagnosed late with severe renal or pulmonary involvement.

Interactions

rs7151526 is distinct from the classical SERPINA1 deficiency alleles (rs28929474, the Z allele E342K, and rs17580, the S allele E264V). The Z allele (rs28929474) is strongly pathogenic for classic AAT deficiency lung and liver disease, and is independently associated with even stronger GPA risk (Meta-OR = 12.60 for the Z allele versus 2.70 for rs7151526 in Banerjee 2022). The related SNP rs28929454 (also studied in the Giardini 2024 mortality cohort) showed even more pronounced survival reduction. Individuals carrying rs7151526-A alongside classical deficiency alleles would likely face compounded risk, though direct interaction data is limited.

The mechanism connects rs7151526 to the broader ANCA vasculitis genetic architecture, which includes variants in CTLA4 (rs231775) and other immune regulatory genes identified in the same meta-analysis. PR3-ANCA positive AAV has distinct genetic risks from MPO-ANCA positive disease, and rs7151526's association appears primarily driven by GPA (PR3-ANCA) cases.

Every day your liver handles a continuous stream of spent red blood cells, converting their released haemoglobin into bilirubin and then rendering that bilirubin water-soluble so it can be excreted in bile. The enzyme that carries out this final conjugation step is UGT1A1¹¹ UGT1A1
UDP-glucuronosyltransferase 1A1, a phase II detoxification enzyme that attaches glucuronic acid to unconjugated bilirubin, making it soluble and excretable, encoded by the UGT1A1 gene on chromosome 2q37. When this enzyme is severely reduced, unconjugated bilirubin — fat-soluble and capable of crossing the blood-brain barrier — accumulates in blood and tissues, causing jaundice and, at extreme levels, neurological damage.

The rs72551348 variant (c.992A>G) causes a glutamine-to-arginine substitution at position 331 of the UGT1A1 protein (p.Gln331Arg, also written Q331R). This missense change disrupts the enzyme's catalytic efficiency for bilirubin conjugation, leaving only a fraction of normal activity. ClinVar classifies it as Pathogenic²² ClinVar classifies it as Pathogenic
RCV000013058, associated with Crigler-Najjar syndrome type II, and it was first described by Moghrabi et al.³³ Moghrabi et al.
Moghrabi N et al. Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2. Genomics, 1993 in a 72-year-old Irish man born of consanguineous parents, whose diagnosis was established when phenobarbital treatment significantly lowered his chronically elevated bilirubin.

The variant affects a shared exon of the UGT1A gene complex, meaning the same nucleotide change disrupts multiple UGT1A isoforms (UGT1A1, UGT1A3–A10 all read from this exon). However, UGT1A1 is the only isoform directly responsible for bilirubin glucuronidation, and Crigler-Najjar syndrome is the primary clinical consequence.

The Mechanism

Gln331 sits in the C-terminal membrane-anchoring domain of UGT1A1, a region important for proper enzyme folding and substrate binding. The arginine substitution introduced by the G allele alters local protein conformation, substantially impairing the enzyme's ability to glucuronidate bilirubin. Unlike type I Crigler-Najjar mutations, which completely abolish UGT1A1 activity, Q331R leaves residual activity — estimated at less than 10% of normal in type II patients — a threshold established by functional expression studies⁴⁴ a threshold established by functional expression studies
Seppen J et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest, 1994. This residual activity is the mechanistic basis for the key clinical feature of type II disease: phenobarbital responsiveness. Phenobarbital is an inducer of UGT1A1 gene expression; boosting transcription from the residual functional allele can meaningfully increase the amount of conjugated bilirubin produced, lowering serum levels by 30% or more.

The Evidence

Crigler-Najjar syndrome type II is rare — fewer than 300 cases have been documented in the medical literature. The Q331R variant (rs72551348) is ultrarare even among UGT1A1 disease alleles, with a G allele frequency of approximately 3.7 × 10⁻⁵ in the gnomAD exome dataset (predominantly in individuals of European ancestry). No homozygous individuals have been observed in population databases, consistent with the rarity of type II Crigler-Najjar syndrome.

Functional characterisation established⁵⁵ Functional characterisation established
Seppen et al. 1994 that the hallmark of type II mutations is partial enzyme inactivation (residual activity 4–38% across patients), versus zero activity in type I. This residual activity keeps serum bilirubin below 20 mg/dL in most type II patients — well below the levels that cause kernicterus — and explains the far better neurological prognosis compared to type I.

A comprehensive genotype-phenotype review⁶⁶ A comprehensive genotype-phenotype review
Kadakol A et al. Hum Mutat, 2000 cataloguing more than 50 UGT1A1 mutations confirmed that the partial-vs-complete enzyme inactivation distinction maps reliably to type II vs type I phenotype, with the critical threshold being whether any residual bilirubin-conjugating activity remains.

Practical Actions

For homozygous carriers (GG) — clinically the relevant genotype for Crigler-Najjar type II — the management priorities are phenobarbital therapy to upregulate residual UGT1A1 expression, bilirubin monitoring, and awareness of drug interactions. Because UGT1A1 metabolises several chemotherapy agents (particularly irinotecan and belinostat), any cancer treatment plan should account for the severely reduced enzyme activity. UV-A phototherapy can be used adjunctively during bilirubin spikes. Liver transplantation is curative and is typically reserved for cases where phenobarbital cannot maintain safe bilirubin levels or when quality of life is severely impaired.

Heterozygous carriers (AG) — one G allele with one normal A allele — have approximately 50% of normal UGT1A1 activity and are clinically normal. Their primary concern is reproductive: if both partners carry a pathogenic UGT1A1 allele, there is a 25% probability of a homozygous child with Crigler-Najjar syndrome.

Interactions

rs72551348 falls on the same UGT1A1 gene that harbours several other clinically significant variants. Compound heterozygosity with the common UGT1A1*28 promoter variant (rs8175347, extra TA repeat reducing expression by ~70% when homozygous) or with *6 Gly71Arg (rs4148323, prevalent in East Asia) can produce a combined UGT1A1 impairment intermediate between Gilbert syndrome and Crigler-Najjar type II. Any individual carrying one Q331R allele should be tested for other UGT1A1 variants, particularly if bilirubin levels are higher than expected for a simple carrier.

Sex hormone-binding globulin is the liver's primary traffic controller for testosterone and estradiol. Only about 1–3% of testosterone circulates as "free" bioactive hormone — the rest is bound to SHBG (roughly 44%) or albumin (54%). When SHBG levels rise, more testosterone gets locked away; when SHBG levels fall, more free testosterone is available to act on tissues. Rs727428 is one of the best-replicated [genetic regulators | This variant has been identified as genome-wide significant in multiple independent GWAS and validated across ancestries] of circulating SHBG levels, located just outside the SHBG gene itself in a downstream regulatory region.

The Mechanism

Rs727428 sits approximately 1 kb downstream of the SHBG gene on chromosome 17p13.1, in a [regulatory region | This area contains chromatin elements that influence SHBG gene expression in the liver; GERP conservation score and Ensembl RegBuild both annotate it as a functional regulatory feature] outside the protein-coding sequence. The variant does not change the SHBG protein structure — it acts by influencing how much SHBG the liver produces. The T allele at this position is associated with reduced SHBG transcription relative to the C allele. Each copy of the T allele reduces serum SHBG by approximately 3–4 nmol/L [| Grigorova et al. 2017, PMID 29264510 — P=7.3×10⁻¹¹, effect −3.74 nmol/L per allele], meaning TT homozygotes produce measurably less SHBG than CC homozygotes. Because SHBG binds testosterone with roughly five times higher affinity than albumin, small changes in SHBG concentration have outsized effects on how much testosterone is biologically active in tissues.

The Evidence

The original genome-wide significant association between rs727428 and circulating SHBG was established in a GWAS of ~1,600 postmenopausal women¹¹ GWAS of ~1,600 postmenopausal women
Prescott et al. PLoS One, 2012 where the T allele was associated with lower SHBG (β=−0.126 on a log scale, P=2.09×10⁻¹⁶). This finding was simultaneously replicated in a GWAS of 3,225 European men²² GWAS of 3,225 European men
Jin et al. Human Molecular Genetics, 2012, where rs727428 showed genome-wide significant associations with both total testosterone (P=1.26×10⁻¹²) and dihydrotestosterone (DHT, P=1.47×10⁻¹¹).

A validation study in 1,687 Japanese men³³ validation study in 1,687 Japanese men
Sato et al. Human Reproduction Open, 2019 replicated the SHBG association (β=0.21, P=3.4×10⁻¹⁰) but did not replicate testosterone association after multiple testing adjustment, suggesting that in East Asian populations the effect on SHBG may not translate directly into measurable testosterone differences — possibly because other loci or lifestyle factors modulate free testosterone differently in this population.

A population-based sibling study of 999 Dutch men⁴⁴ population-based sibling study of 999 Dutch men
Walravens et al. Journal of Clinical Endocrinology & Metabolism, 2025 found that rs727428 T allele homozygotes had 10.8–23.1% lower SHBG and 3.9–21.4% lower total testosterone compared to CC homozygotes. Notably, calculated and directly measured free testosterone showed minimal difference across genotypes — suggesting the body compensates for SHBG-driven total testosterone changes by adjusting LH/FSH feedback to maintain free testosterone homeostasis in healthy men.

In women, a Mediterranean PCOS case-control study of 1,004 premenopausal women⁵⁵ Mediterranean PCOS case-control study of 1,004 premenopausal women
Martínez-García et al. Human Reproduction, 2012 found the T allele was more frequent in PCOS patients than controls (OR=1.29), independent of obesity. A family-based PCOS study in 758 women⁶⁶ family-based PCOS study in 758 women
Wickham et al. Journal of Clinical Endocrinology & Metabolism, 2011 confirmed that rs727428 genotype was independently associated with SHBG levels after controlling for BMI, insulin resistance, and free testosterone. Meta-analyses have shown mixed results: one 2020 meta-analysis (1,660 cases, 1,312 controls) found the association with PCOS susceptibility was not statistically significant after pooling, while individual studies — particularly in Mediterranean and Middle Eastern populations — consistently found associations. The discrepancy likely reflects population-specific allele frequencies and PCOS diagnostic heterogeneity.

Practical Implications

The clinical consequences of rs727428 depend heavily on context. In women, lower SHBG from the T allele means more free testosterone and a higher [free androgen index | FAI = total testosterone ÷ SHBG × 100; values above 4–5 in women are associated with androgenic symptoms and PCOS]. Women with TT genotype benefit most from monitoring free androgen index rather than total testosterone, and from strategies that support SHBG production — particularly insulin-sensitizing approaches, since insulin is a potent suppressor of hepatic SHBG synthesis. In men, lower SHBG generally keeps more testosterone available in tissue, but the Walravens 2025 data suggest the body's hormonal feedback loop largely compensates in healthy young men. Where this compensation may fail is in older men, men with metabolic syndrome, and men undergoing testosterone monitoring for hypogonadism — in these contexts, SHBG genotype should inform how total testosterone is interpreted.

Interactions

rs1799941 (SHBG promoter G-68A): This variant in the SHBG promoter acts independently from rs727428 to regulate SHBG levels. The A allele of rs1799941 increases SHBG by 15–25%, opposing the T allele effect at rs727428. The Grigorova 2017 study (PMID 29264510) found these variants replicate independently — both are significant GWAS hits with distinct mechanisms (one alters promoter transcription factor binding; the other affects downstream regulatory architecture). A person carrying T at rs727428 AND G at rs1799941 has two additive SHBG-lowering variants; a person carrying T at rs727428 AND A at rs1799941 has opposing forces that may partially cancel. This is a strong candidate for a compound action given the opposite-direction effects in the same pathway.

rs6259 (SHBG Asp327Asn): A missense variant in the SHBG protein (p.Asp327Asn) that reduces testosterone binding affinity by approximately 10%, thereby increasing free testosterone bioavailability even when total SHBG concentration is unaffected. In men, the A allele of rs6259 was associated with increased free testosterone in the Walravens 2025 study. Compound carriers of both the rs727428 T allele (less SHBG protein) and the rs6259 A allele (SHBG protein with lower binding affinity) would have a compounded increase in free testosterone — relevant for interpreting androgen status in both sexes.

Compound action proposal for rs727428 TT + rs1799941 GG: Women carrying TT at rs727428 AND GG at rs1799941 carry two independent SHBG-lowering variants — one reducing transcription rate (promoter), one reducing downstream regulatory expression. The combined recommendation: measure free androgen index (FAI = total testosterone ÷ SHBG × 100); track SHBG as a metabolic risk biomarker; implement insulin-sensitizing strategies (inositol supplementation has evidence for PCOS with low SHBG); and discuss combined SHBG genotype result with clinician before interpreting any sex hormone panel. Evidence level: moderate (individual effects well-established; combined effect inferred from independent pathway data).

The LDL receptor (LDLR) encoded by the LDLR gene is the primary mechanism by which the liver clears low-density lipoprotein (LDL) cholesterol from the bloodstream. Each functional LDLR molecule captures LDL particles at the hepatocyte surface and draws them into the cell via receptor-mediated endocytosis, where cholesterol is released for cellular use. Pathogenic LDLR mutations disrupt this clearance system, allowing LDL cholesterol to accumulate in the blood from birth — the defining feature of familial hypercholesterolemia (FH)¹¹ familial hypercholesterolemia (FH)
autosomal dominant disorder causing severe, lifelong LDL-C elevation and dramatically accelerated atherosclerosis.

rs730882105 is an extremely rare missense variant in LDLR that substitutes methionine for valine at amino acid position 524 (c.1570G>A, p.Val524Met). It has been classified as likely pathogenic by the British Heart Foundation LDLR-LOVD database²² likely pathogenic by the British Heart Foundation LDLR-LOVD database
the LDLR Leiden Open Variation Database maintained by the BHF is the most comprehensive curated registry of LDLR variants with clinical significance assignments, though a second submitter classified it as uncertain significance under stricter ACMG 2015 criteria, and a Merck Research Labs functional study found no significant impairment in vitro. The conflicting evidence reflects a genuine ambiguity in this rare variant: population frequency is too low for robust statistical association, and functional assay results diverge from clinical reports. This YAML entry reflects the intermediate evidence state.

The Mechanism

Val524 sits within the [ligand-binding domain cluster of LDLR | the extracellular ligand-binding domain consists of seven cysteine-rich repeats (LBD1–7) that directly contact apolipoprotein B-100 on LDL particles and apolipoprotein E on VLDL/IDL particles] — specifically in or near repeat 7 (LBD-7), a region required for efficient LDL binding and cellular uptake. Valine-to-methionine substitutions introduce a larger, more polar side chain that can disrupt the local protein conformation, though the magnitude of functional impairment varies by exact position and surrounding structure. The Merck in vitro data suggesting no effect may reflect assay conditions not replicating the full hepatic context of LDL binding and recycling; real-world FH reports in carriers are the stronger signal for a receptor with known genotype-phenotype correlation.

Untreated heterozygous FH (one mutated LDLR copy) typically produces LDL-C of 190–400 mg/dL from birth — levels that accelerate atherosclerotic plaque formation decades earlier than in the general population. Ference et al. 2017³³ Ference et al. 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal established that the cumulative LDL burden from birth (not just current levels) drives atherosclerosis; this is why FH carriers begin accumulating plaques in their teens and 20s and may have their first myocardial infarction before age 50.

The Evidence

rs730882105 is too rare (2 alternate alleles in 1.4 million gnomAD samples) to accumulate direct statistical evidence for this specific variant. Its likely pathogenic classification rests on: (1) location in a functionally critical LDLR domain; (2) clinical reports of FH phenotype in at least one carrier submitted to the LDLR-LOVD; (3) the prior probability that missense variants disrupting LDLR ligand-binding repeats are pathogenic, which is high based on the 3,200+ characterized LDLR variants catalogued by Abifadel & Boileau 2023⁴⁴ Abifadel & Boileau 2023
Genetic and molecular architecture of familial hypercholesterolemia. J Intern Med, where missense variants account for ~60% of all pathogenic LDLR mutations.

The broader FH evidence base is compelling: untreated heFH carries a [substantially elevated risk of CHD | coronary heart disease — up to 13-fold excess risk per the EAS consensus] Defesche et al. 2017⁵⁵ Defesche et al. 2017
Familial hypercholesterolaemia. Nat Rev Dis Primers. The global prevalence of FH is approximately 1:250 (1:80 in founder populations such as French Canadians and Afrikaners) — far higher than previously thought. Most remain undiagnosed. Tokgozoglu & Kayikcioglu 2021⁶⁶ Tokgozoglu & Kayikcioglu 2021
Familial Hypercholesterolemia: Global Burden and Approaches. Curr Cardiol Rep estimated that >85% of FH individuals globally are undetected. With statin therapy achieving ≥50% LDL reduction, the excess cardiovascular risk is substantially attenuated — making early identification and treatment directly life-extending.

Practical Actions

Heterozygous carriers of rs730882105 should have a fasting lipid panel performed to establish baseline LDL-C levels. LDL-C >190 mg/dL in an adult with a likely pathogenic LDLR variant typically meets criteria for high-intensity statin therapy (rosuvastatin 20–40 mg or atorvastatin 40–80 mg). The LDL-C target is <100 mg/dL for those without established cardiovascular disease, and <70 mg/dL for those with prior ASCVD events. If statin therapy alone is insufficient, ezetimibe (adds ~15% LDL reduction) and PCSK9 inhibitors (alirocumab, evolocumab — add ~50% LDL reduction) are guideline-recommended additions. Sturm et al. 2018⁷⁷ Sturm et al. 2018
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel recommends cascade screening of all first-degree relatives when a pathogenic LDLR variant is identified — each child of a carrier has a 50% chance of inheriting the mutation.

Saturated fat restriction to below 7% of total calories specifically reduces hepatic LDL production and complements statin therapy in FH; this is one of few dietary interventions with FH-specific evidence because it operates through the same LDL-receptor pathway that LDLR mutations impair.

Interactions

LDLR variants interact in severity with PCSK9 gain-of-function variants (rs28942078, rs72658867) and APOB p.Arg3527Gln: carriers of both a pathogenic LDLR variant and a PCSK9 gain-of-function variant have substantially more severe LDL elevation than either alone, as PCSK9 degrades the LDL receptor — compounding the LDLR mutation's reduced receptor availability. Double heterozygotes are estimated to have FH severity approaching homozygous FH. APOE ε4 (rs429358) also modestly elevates LDL-C and is relevant context for cardiovascular risk assessment in carriers.

The region just upstream of HLA-DRA on chromosome 6p21.32 is home to one of the most powerful common genetic risk signals for rheumatoid arthritis (RA) in the human genome. rs9268839 is an intergenic variant located approximately 16 kilobases upstream of HLA-DRA¹¹ HLA-DRA
HLA class II histocompatibility antigen, DR alpha chain — the gene encoding the alpha subunit of the HLA-DR heterodimer on antigen-presenting cells, within a dense cluster of HLA class II genes including HLA-DRB5, HLA-DRB9, and TSBP1. The G allele carries an odds ratio of approximately 2.47 per copy for RA in European populations — among the largest effect sizes of any common non-coding variant discovered in autoimmune disease genetics.

The Mechanism

HLA-DRA encodes the invariant alpha chain of the HLA-DR molecule, a class II major histocompatibility complex (MHC) protein expressed on the surface of antigen-presenting cells — dendritic cells, macrophages, and B cells. HLA-DR is a heterodimer: the alpha chain (encoded by HLA-DRA) pairs with a beta chain (encoded by HLA-DRB1, DRB3, DRB4, or DRB5 depending on the haplotype). The combined molecule presents peptide fragments from pathogens and self-proteins to CD4+ helper T cells, initiating adaptive immune responses. The critical insight is that HLA-DRA is largely non-polymorphic²² HLA-DRA is largely non-polymorphic
Unlike HLA-DRB1, which has hundreds of functionally distinct alleles, HLA-DRA varies very little between individuals — its alpha chain is nearly identical across all people. rs9268839 is therefore not a coding variant in HLA-DRA itself, but a tag SNP marking an extended haplotype block that includes the HLA-DRB5 locus and influences local regulatory architecture through linkage disequilibrium with functional variants in flanking HLA-DRB genes.

The precise functional variant this SNP tags has not been fully resolved — a common situation in the HLA region, where extreme polymorphism and LD make fine-mapping challenging. What is clear is that the G-allele haplotype is enriched for HLA-DR conformations that present citrullinated self-peptides particularly efficiently to autoreactive CD4+ T cells, driving the production of anti-citrullinated protein antibodies (ACPA)³³ anti-citrullinated protein antibodies (ACPA)
The hallmark autoantibody in seropositive RA; detected by the anti-CCP test and predictive of joint erosion — the defining pathological antibodies in seropositive RA.

The Evidence

Rheumatoid arthritis. The GWAS signal at rs9268839 is among the most replicated findings in autoimmune genetics. In the landmark Okada et al. 2014 meta-analysis⁴⁴ Okada et al. 2014 meta-analysis
Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 29,880 RA cases and 73,758 controls spanning European and Asian populations, the HLA class II locus at chromosome 6p21.32 (of which rs9268839 is a primary tag) showed the strongest association in the entire genome. In the Laufer et al. 2019 trans-ethnic fine-mapping study⁵⁵ Laufer et al. 2019 trans-ethnic fine-mapping study
Genetic influences on susceptibility to rheumatoid arthritis in African-Americans. Hum Mol Genet 2019; 916 AA cases + >100,000 European/East Asian participants, the HLA-DRB1/DRA region reached p<1×10⁻²⁵⁰ in Europeans — the maximum reportable significance threshold. The rs9268839-G allele carries an OR of approximately 2.47 (95% CI 2.39–2.55) in European cohorts and 1.90 (95% CI 1.81–1.99) in East Asian cohorts, both at p=1×10⁻²⁵⁰.

Sarcoidosis. The G allele at rs9268839 has also been implicated in sarcoidosis susceptibility, a granulomatous inflammatory disease driven by dysregulated antigen presentation in the lung and lymph nodes. In Levin et al. 2013⁶⁶ Levin et al. 2013
Association of ANXA11 genetic variation with sarcoidosis in African Americans and European Americans. Genes Immun 2013; 1,689 cases and 1,252 controls, rs9268839 near HLA-DRA was identified as a sarcoidosis risk SNP showing significant SNP-SNP interaction with ANXA11 rs1049550, suggesting that the HLA-DRA region risk variant amplifies disease susceptibility when combined with ANXA11 variants that impair calcium-dependent immune regulation.

Practical Actions

Carrying one or two G alleles does not mean RA or sarcoidosis will develop — these are probabilistic risk elevations, not deterministic outcomes. However, G carriers should be alert to early symptoms and pursue earlier investigation when musculoskeletal symptoms appear. The most actionable step for G carriers is anti-CCP antibody testing: ACPA can appear years before clinical RA and predicts severity and progression. G carriers who are also ACPA-positive should seek rheumatology review proactively.

Smoking is the most important environmental co-trigger: the HLA class II region and cigarette smoke interact to produce citrullinated lung antigens that drive ACPA production, multiplying RA risk superadditively in G-allele carriers.

Interactions

rs9268839 operates in the same antigen-presentation pathway as rs660895 (HLA-DRB1 shared epitope tag), rs6910071 (TSBP1/C6orf10 intronic variant), and rs2476601 (PTPN22 R620W). These variants act at distinct steps — peptide groove composition, MHC region haplotype structure, T-cell receptor signalling — and their co-occurrence is associated with multiplicative rather than additive RA risk. rs9268839 and rs660895 are in moderate LD in Europeans and may partly tag the same underlying haplotype, but they are not fully redundant: rs9268839 explains additional variation in RA susceptibility beyond the shared epitope alone.

The IL1RL1 gene¹¹ IL1RL1 gene
Interleukin-1 Receptor-Like 1, encoding the ST2 protein — the primary cell-surface receptor for the alarmin cytokine IL-33, expressed on mast cells, eosinophils, ILC2s, and Th2 lymphocytes is one of the most replicated loci in allergy and asthma genetics. Most research focuses on variants that increase risk. rs13424006 is notable for the opposite reason: the C allele at this intronic position is protective — carriers have a measurably lower risk of developing late-onset wheeze, the wheezing phenotype most strongly linked to persistent adult asthma.

The IL-33/ST2 axis functions as an epithelial damage alarm. When airway cells are injured by viruses, allergens, or pollutants, they release IL-33²² IL-33
A nuclear alarmin cytokine that, when released from damaged epithelial cells, binds to ST2 on ILC2s, mast cells, and eosinophils, triggering a rapid Th2 cascade. The intensity of that alarm depends on the ratio between membrane-bound ST2 (which transmits the signal) and soluble sST2 (which mops up free IL-33 before it can reach its target cells). IL1RL1 variants modulate this ratio — some increasing signalling capacity, others buffering it. rs13424006 sits in the intron where this regulatory balance is calibrated.

The Mechanism

rs13424006 maps to position 102,350,776 on chromosome 2 (GRCh38), within the 10th intron of IL1RL1. Like rs10208293 — the other intronic IL1RL1 variant that specifically tags late-onset wheeze in the same study — rs13424006 is presumed to act through an eQTL mechanism, influencing the relative production of membrane-bound IL1RL1 and the soluble decoy sST2 without altering the protein sequence. The C allele tags a haplotype associated with more effective IL-33 buffering: greater production or activity of sST2, which intercepts IL-33 before it activates eosinophils and ILC2s.

rs13424006 and rs10208293 both sit in the 10th intron and both specifically associate with the late-onset wheeze phenotype, but they are genotyped separately and may tag distinct regulatory elements within the same intronic region. Whether their effects are additive, redundant, or mechanistically coupled is not yet established.

The Evidence

The protective effect of the C allele was first defined in a large two-cohort study by Savenije et al. (2014)³³ Savenije et al. (2014), which meta-analysed data from 2,007 children in the Dutch PIAMA cohort and 7,247 children in the UK ALSPAC cohort, following wheeze phenotypes from birth to age 8. The analysis distinguished four phenotypes: no wheeze, early-transient wheeze, intermediate-onset, and late-onset wheeze. rs13424006 was one of only two IL1RL1 SNPs that associated specifically with late-onset wheeze (OR approximately 0.74, 95% CI 0.63–0.87), meaning C allele carriers develop this phenotype at substantially lower rates than TT homozygotes.

The late-onset specificity is clinically important. Late-onset wheeze — wheeze that develops after the toddler years, typically in mid-childhood — has a much stronger association with persistent adult asthma than early-transient wheeze, which is largely virus-driven and often resolves. The IL-33/ST2 pathway specifically drives the eosinophilic subtype⁴⁴ eosinophilic subtype
Eosinophilic asthma is characterised by airway eosinophilia, elevated FeNO, and good response to inhaled corticosteroids and IL-5/IL-13 pathway biologics of asthma that underlies most late-onset disease.

Confirmation came from Chinese Han children (265 asthma cases, 153 controls) in Wu et al. (2021)⁵⁵ Wu et al. (2021), where CT or CC genotypes were associated with lower asthma susceptibility (adjusted OR 0.584, 95% CI 0.362–0.941, p=0.027) and, in those with asthma, a lower probability of elevated FeNO at baseline (adjusted OR 0.286, 95% CI 0.125–0.652, p=0.003). The FeNO finding directly connects genotype to eosinophilic airway inflammation — the mechanism the IL-33/ST2 axis drives.

Fourteen years of IL1RL1 population genetics, most recently summarised in Savenije et al. (2011)⁶⁶ Savenije et al. (2011), established that 13 of 15 IL1RL1 SNPs tested were significantly associated with circulating sST2 levels in childhood, confirming the IL1RL1 locus as the primary genetic determinant of the soluble decoy receptor that buffers IL-33 signalling.

Practical Implications

For TT homozygotes, the actionable priority is awareness and monitoring. The TT genotype represents the population baseline — lacking the extra sST2-buffering effect the C allele confers. This does not mean TT individuals are at elevated risk in an absolute sense; it means they do not carry the C allele's protective advantage. If there is any history of childhood wheeze, asthma, or respiratory allergy, checking FeNO is the highest-yield approach to characterise whether eosinophilic airway inflammation is present — and whether eosinophil-targeting treatments (ICS, dupilumab, mepolizumab, benralizumab, itepekimab) would be particularly well-matched.

For CC homozygotes, the protective genotype reduces eosinophilic airway inflammation risk through this particular regulatory element — but this doesn't override other asthma risk factors and shouldn't be interpreted as blanket protection against all respiratory allergy.

Interactions

rs13424006 and rs10208293 both tag the late-onset wheeze phenotype at the IL1RL1 locus, sitting in the same intronic region (10th intron). Their effects may reflect distinct regulatory elements — having the protective C allele at rs13424006 alongside a risk allele at rs10208293 may represent partial compensation rather than full protection.

The IL-33 ligand variant rs992969 determines how much IL-33 is produced upstream. A TT carrier at rs13424006 who also carries the IL-33 production-increasing allele at rs992969 faces elevated ligand meeting reduced buffering — a combined effect on the entire axis. The TSLP variant rs1837253 acts upstream in the same Th2 cascade; multiple risk alleles in this pathway produce substantially higher cumulative eosinophilic inflammation risk than any single SNP predicts.

Your body runs on a 24-hour clock, and melatonin is its timekeeper. As darkness falls, melatonin rises — signaling sleep, lowering core body temperature, and, critically, telling your pancreatic beta cells to reduce insulin secretion until morning. The MTNR1B gene encodes the melatonin receptor type 2¹¹ melatonin receptor type 2
A G-protein-coupled receptor (MT2) expressed in the brain, retina, and — importantly — pancreatic beta cells, where it directly suppresses glucose-stimulated insulin release via inhibitory cAMP signaling (MT2) that mediates this signal in pancreatic beta cells.

The rs1562444 variant sits in the 3' untranslated region of MTNR1B — not in the protein-coding sequence, but in the regulatory tail of the gene's messenger RNA. This position places it within a region governing mRNA stability, turnover, and post- transcriptional control, including potential microRNA binding sites. Individuals carrying the G allele — the reference allele at this position, but the global minority allele (~44% worldwide, ~50% in Europeans) — show differences in circulating melatonin levels²² differences in circulating melatonin levels
Wang et al. 2019 (PMID 31815152) reported significant differences in plasma melatonin concentrations between rs1562444 genotypes compared to AA homozygotes, consistent with altered MTNR1B expression or signaling efficiency.

The Mechanism

Variants in the 3' UTR do not change the receptor protein itself but can alter how much MTNR1B is produced. This region contains AU-rich elements³³ AU-rich elements
Sequences in mRNA that govern degradation rate — more instability signals mean lower protein output that influence mRNA half-life and regulate microRNA binding. A single nucleotide change at position c.*371 (NM_005959.5:c.*371G>A) can shift the binding affinity of endogenous microRNAs or RNA-binding proteins that control MTNR1B transcript abundance.

More MTNR1B protein on beta cells means stronger melatonin-mediated suppression of cAMP and, therefore, reduced glucose-stimulated insulin secretion — particularly in the hours after sunset when melatonin is rising. The rs1562444 G allele appears to influence this expression level in the same direction as the well-established intronic risk variant rs10830963⁴⁴ rs10830963
The strongest GWAS hit for fasting glucose in the MTNR1B locus, present in 28% of Europeans, with P=3.2×10⁻⁵⁰ in the original discovery; already profiled separately in this encyclopedia, with which it shares partial linkage disequilibrium⁵⁵ linkage disequilibrium
A statistical tendency for nearby variants to be inherited together, meaning alleles at one site predict alleles at nearby sites within a population in the MTNR1B haplotype block.

The Evidence

The primary evidence for rs1562444 comes from several independent contexts. Wang et al. 2019⁶⁶ Wang et al. 2019
Wang P et al. Association of Melatonin Pathway Gene's Single-Nucleotide Polymorphisms with Systemic Lupus Erythematosus in a Chinese Population. J Immunol Res, 2019 genotyped 11 MTNR1B tag SNPs including rs1562444 in 495 SLE patients and 493 controls, reporting that rs1562444 genotype was associated with significant differences in plasma melatonin levels — direct biological evidence that this UTR variant modulates MTNR1B signaling output.

Robeva et al. 2023⁷⁷ Robeva et al. 2023
Robeva R et al. Melatonin Receptor 1B and Corticosteroid Receptor Polymorphisms in Infertile Women with Implantation Failure and Miscarriages. Front Biosci, 2023 found that G-allele- containing genotypes (AG+GG) were significantly enriched in 111 infertile women with recurrent implantation failure compared to 106 controls (19.3% vs. 3.6%, p=0.004), extending the MTNR1B signaling effect into reproductive physiology.

At the wider locus level, the landmark Prokopenko et al. 2009⁸⁸ Prokopenko et al. 2009
Prokopenko I et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet, 2009 and Bouatia-Naji et al. 2009⁹⁹ Bouatia-Naji et al. 2009
Bouatia-Naji N et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet, 2009 GWAS studies established that regulatory variation across the MTNR1B locus drives fasting glucose elevation (beta 0.06–0.07 mmol/L per risk allele) and type 2 diabetes risk (OR 1.09–1.15) in tens of thousands of Europeans.

Evidence for rs1562444's independent metabolic effect is emerging rather than established — its metabolic significance is partly inherited from its position within the MTNR1B haplotype block rather than from direct functional studies of this specific UTR position.

Practical Actions

The actionable guidance for MTNR1B G-allele carriers at rs1562444 mirrors the meal-timing interventions validated for the stronger intronic variants: eating earlier in the day, avoiding late dinners, and aligning meals with the low-melatonin window protect beta-cell function when melatonin receptor activity is elevated. Lopez-Minguez and Garaulet et al. 2018¹⁰¹⁰ Lopez-Minguez and Garaulet et al. 2018
Lopez-Minguez J et al. Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: a randomized, cross-over study. Clin Nutr, 2018 demonstrated in a randomized crossover trial that late dinner impairs glucose tolerance specifically in MTNR1B risk allele carriers.

Monitoring fasting glucose and HbA1c at recommended intervals provides the earliest warning if the metabolic effect begins to compound over time, especially for G-allele carriers who also eat late habitually.

Interactions

The MTNR1B locus contains several variants in partial LD that have been studied independently. The intronic rs10830963 (already profiled in Hormones & Sleep) is the strongest metabolic signal at this locus, while rs1562444 and the coding variant rs3781637 (G24E) represent additional dimensions of MTNR1B regulation. Co-carriage of rs1562444 G with the rs10830963 G risk haplotype could compound melatonin receptor overexpression in beta cells, though this specific interaction has not been formally modeled. Individuals carrying risk alleles at both rs1562444 and rs10830963 represent a subset worth considering for compound action guidance (see related SNP rs10830963 for the meal-timing intervention with the strongest published evidence).

Every protein your neurons need to maintain their mitochondria must be physically imported across the outer mitochondrial membrane. The protein that guards this gateway is TOM40, encoded by TOMM40¹¹ TOMM40
Translocase of Outer Mitochondrial Membrane 40; one of the core components of the TOM complex, the main protein-import channel for the outer mitochondrial membrane. When TOMM40 function is compromised in neurons, mitochondrial biogenesis slows, ATP production falls, and the cellular stress that precedes neurodegeneration begins to accumulate. rs157582 sits in an intron of this gene on chromosome 19 — in the same genomic neighborhood as the better-known APOE variants — and is associated in multiple large population studies with accelerated memory decline and faster hippocampal shrinkage in aging.

The Mechanism

rs157582 is a non-coding intronic variant; it does not directly change the TOM40 protein sequence. Its effect is regulatory: the variant likely influences TOMM40 transcription levels, mRNA splicing, or local gene regulation within the densely packed APOE/TOMM40/APOC1 locus²² APOE/TOMM40/APOC1 locus
These three genes on chromosome 19q13.32 are in partial linkage disequilibrium; rs157582 in TOMM40 is physically between APOE and TOMM40 and multiple variants in this region are in LD with APOE ε4, though rs157582 has documented effects independent of APOE ε4 genotype.

The mechanistic link between TOMM40 variation and neurodegeneration involves two converging pathways. First, Alu retrotransposon insertions in TOMM40 introns³³ Alu retrotransposon insertions in TOMM40 introns
Alu elements are primate-specific repetitive DNA sequences; at least one Alzheimer's disease-associated TOMM40 variant originated from an Alu insertion event per Larsen et al. 2017 can disrupt mRNA processing via aberrant splicing and A-to-I RNA editing, reducing functional TOM40 protein levels in neurons. Reduced TOM40 channel activity impairs mitochondrial protein import, lowering the supply of nuclear-encoded subunits needed for oxidative phosphorylation complexes. In neurons — which are uniquely dependent on mitochondria given their high energy demands and inability to rely on glycolysis — even partial TOM40 insufficiency accelerates mitochondrial dysfunction with age.

Second, dysfunctional TOMM40 activates neuroinflammatory cascades. TOMM40 loss-of-function experiments in microglial cells demonstrate NF-κB pathway activation and NLRP3 inflammasome assembly⁴⁴ NF-κB pathway activation and NLRP3 inflammasome assembly
The NLRP3 inflammasome is a multiprotein complex that cleaves pro-IL-1β into its active form; its chronic activation in microglia is a hallmark of late-stage Alzheimer's disease pathology, with downstream secretion of IL-1β, IL-6, and TNF-α — pro-inflammatory cytokines that damage synapses and accelerate amyloid-beta and tau accumulation.

The Evidence

The largest genetic epidemiology evidence comes from a GWAS of aging-related verbal memory⁵⁵ GWAS of aging-related verbal memory
Combined analysis of the Health and Retirement Study (HRS; N=7,486 genotyped) and English Longitudinal Study of Ageing (ELSA; N=6,898), measuring longitudinal immediate and delayed recall performance across multiple waves. rs157582 reached genome-wide significance for both immediate recall change after age 60 (meta-analysis p=8.3×10⁻¹⁰) and delayed recall level (p=7.0×10⁻⁹). Critically, conditional analyses demonstrated that the signal on immediate recall change was driven by TOMM40, not APOE — providing the strongest evidence to date that rs157582 influences memory aging through a partially independent mechanism.

Brain imaging corroborates this. In 602 non-demented elders from the ADNI cohort⁶⁶ 602 non-demented elders from the ADNI cohort
Alzheimer's Disease Neuroimaging Initiative; participants were non-Hispanic Caucasian adults without dementia at enrollment, followed longitudinally for hippocampal volume changes by MRI, the T allele of rs157582 was associated with faster hippocampal atrophy rate in a dose-dependent manner (p=1.23×10⁻⁸, genome-wide significant). T allele carriers showed lower Mini-Mental State Examination scores and higher Alzheimer's Disease Assessment Scale cognitive subscale scores, linking the genetic signal directly to measurable brain and cognitive outcomes even before dementia onset.

rs157582 also reaches genome-wide significance in GWAS for Alzheimer's disease itself (OR≈2.73 overall; OR≈2.83 in males, OR≈2.62 in females per Nazarian et al. 2019, PMID 30636644), and for CSF biomarkers of AD pathology including reduced Aβ1-42 (p=1×10⁻²³) and altered tau-to-Aβ ratios — the cerebrospinal fluid fingerprint of amyloid accumulation and tau hyperphosphorylation that precedes clinical dementia by 10–15 years.

Practical Actions

For T allele carriers, the actionable focus is on interventions that specifically support mitochondrial efficiency and limit neuroinflammatory burden. The critical distinction from APOE-focused guidance is timing: because the TOMM40 effect is strongest on rate of change in memory during normal aging (not just dementia risk), interventions aimed at preserving mitochondrial health are relevant decades before any cognitive symptoms emerge.

Coenzyme Q10 (ubiquinol form) directly supports mitochondrial electron transport chain efficiency. Creatine monohydrate supplements the phosphocreatine system that neurons use to buffer ATP supply during periods of high demand. DHA (the omega-3 found predominantly in brain tissue) maintains mitochondrial membrane fluidity, directly affecting the TOM complex's functional environment. These are not generic brain-health supplements — they target the specific mitochondrial import and energy production pathway that TOMM40 variation affects.

Cognitive baseline testing provides a concrete neurological anchor: by documenting your memory performance in your 40s or 50s (using validated tools like the MoCA, or a comprehensive neuropsychological battery), you create a personalized reference point that makes meaningful future change detectable much earlier than population-average norms allow.

Interactions

rs157582 sits within the APOE/TOMM40/APOC1 locus on chromosome 19, meaning it is in partial linkage disequilibrium with APOE ε4 (rs429358 T allele) and APOE ε2 (rs7412 T allele). However, the GWAS evidence distinguishes the signals: APOE drives delayed recall level, while TOMM40 rs157582 drives the rate of immediate recall change after age 60. Individuals carrying both rs157582 T and APOE ε4 face additive neurodegeneration risk from two partially independent biological pathways — amyloid clearance (APOE) and mitochondrial protein import efficiency (TOMM40). rs2075650, another TOMM40 intron variant, shows similar associations with cognitive aging but some fine-mapping studies suggest its signal is attributable to APOE ε4 LD rather than independent TOMM40 effect. rs10524523, the TOMM40 intron 6 poly-T variable-length polymorphism, has been studied specifically for Alzheimer's age-of-onset prediction and represents a separate functional variant in the same gene.

MTRR (methionine synthase reductase) is the enzyme that keeps methionine synthase ¹¹ MTR: the enzyme that converts homocysteine to methionine using methylcobalamin (active B12) as a cofactor (MTR) running. During normal operation, MTR oxidizes its methylcobalamin cofactor to an inactive cob(II)alamin form — and it is MTRR's job to reduce it back to active methylcobalamin so MTR can continue. Without functional MTRR, MTR activity declines, homocysteine accumulates, and the methylation cycle slows.

rs162049 is an intronic variant — it sits within an intron of MTRR and does not directly change the protein sequence. Its significance lies in its membership in a functional haplotype: the G-allele risk haplotype is associated with reduced MTRR protein expression, meaning less enzyme is produced rather than less efficient enzyme. The net effect is the same: less B12 reactivation capacity, slower homocysteine remethylation, and altered DNA methylation patterns.

The Mechanism

The G allele at rs162049 co-segregates with a risk haplotype in the MTRR gene. Functional studies with transfected cell lines showed that this haplotype produced significantly lower MTRR protein levels compared to the wild-type haplotype, resulting in elevated homocysteine in culture medium and reduced LINE-1 methylation²² elevated homocysteine in culture medium and reduced LINE-1 methylation
Ohnami S et al. His595Tyr polymorphism in MTRR associated with pancreatic cancer risk. Gastroenterology, 2008 — a marker of global genomic methylation status. This is consistent with MTRR's central role: reduced B12 reactivation → reduced MTR activity → homocysteine accumulation → impaired one-carbon cycle → hypomethylation.

The Evidence

A multicenter Japanese case-control study ³³ Ohnami S et al. Gastroenterology 2008 — 317 pancreatic cancer cases vs 1,232 controls identified rs162049 as an independent risk-associated variant for pancreatic cancer (OR 1.33, 95% CI 1.11–1.60; P = 0.0018). The association survived permutation testing under a recessive model (P = 0.024). A separate case-control study ⁴⁴ Sangrajrang S et al. Breast Cancer Res Treat 2010 — 570 cases / 497 controls in Thai women in Thai women found that the G allele was associated with increased breast cancer risk in postmenopausal women (OR 1.61, 95% CI 1.07–2.44), consistent with impaired methylation-dependent gene regulation. A cross-sectional study ⁵⁵ Ono H et al. Cancer Science 2012 — 384 Japanese women of 384 Japanese women found no independent effect of rs162049 on global leukocyte DNA methylation, suggesting the variant's functional impact may require haplotype context or additional environmental pressures (low B12, low folate intake).

The evidence overall is emerging: consistent biological plausibility and two independent cancer-risk associations, but no large-cohort homocysteine quantification or randomized intervention data specific to this variant.

Practical Implications

Because the G allele affects MTRR expression rather than enzyme structure, the intervention strategy focuses on reducing downstream demand rather than bypassing the enzyme. Ensuring sufficient methylcobalamin supply gives MTR more substrate to work with, partially compensating for reduced MTRR recycling capacity. Methylfolate (5-MTHF) keeps the methyl-donor pool full upstream. Monitoring plasma homocysteine provides an objective readout of whether the methylation cycle is under strain.

Interactions

rs162049 is most significant in combination with the MTRR A66G missense variant (rs1801394), which reduces enzyme efficiency — stacking reduced expression (rs162049) with reduced efficiency (rs1801394) compounds B12-reactivation impairment. Combined with MTHFR C677T (rs1801133), which limits methylfolate supply upstream, or MTR A2756G (rs1805087), which reduces methionine synthase activity directly, the effect on homocysteine clearance and DNA methylation is substantially amplified. The intronic SNP rs10380 (His595Tyr, MTRR) was co-identified in the same pancreatic cancer haplotype analysis and likely tags the same functional haplotype.